Home Therapeutic relationship NIH and GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

NIH and GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants


News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

BOSTON, July 29. 12, 2022 (GLOBE NEWSWIRE) — GreenLight Biosciences announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that more broadly protect against new variants and with longer lasting effects.

“This is a tremendous opportunity for us to partner with a leading vaccine discovery team and use our mRNA platform to accelerate the development of coronavirus vaccines that are more broadly protective and durable than those currently available. available,” says Amin Khan, PhD, Scientific Director of GreenLight. Officer, Human Health.

GreenLight, in collaboration with the Vaccine Research Center (VRC), part of the NIH’s National Institute of Allergy and Infectious Diseases, will co-design and test mRNA coronavirus vaccines with the goal of developing vaccines that confer a longer lasting immune response than current vaccines. Additionally, they will work together to develop systems that accelerate the clinical use of new designs.

SARS-CoV-2, the virus that causes COVID-19, continues to evolve and accumulate genomic mutations that may negatively affect the effectiveness of existing medical countermeasures. For the current COVID-19 pandemic and future coronavirus-related pandemics, the rapid development and deployment of vaccines active against a range of coronaviruses, including variants of SARS-CoV-2, will be vital for public health.

According to the NIH, Cooperative Research and Development Agreements, or CRADAs, “provide NIH researchers with an exciting opportunity to join colleagues in industry and academia in the joint pursuit of common research goals. Government scientists serve the larger mission of the NIH, to facilitate the development and commercialization of pharmaceutical and health care products. Companies can also leverage their own R&D efforts while collaborating on cutting-edge NIH research. »

About GreenLight BiosciencesGreenLight Biosciences aims to solve some of the world’s biggest problems by harnessing the full potential of RNA for human health and agriculture. Our RNA platform enables us to research, design and manufacture for human, animal and plant health. In human health, this includes vaccines and messenger RNA therapeutics. In agriculture, this includes RNA to protect bees and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the preclinical stage, and its agricultural market product candidates are in the early stages of development or regulatory review. GreenLight is a utility company that trades under the symbol GRNA on the Nasdaq. For more information visit https://www.greenlightbiosciences.com/

ContactDavid PesciHead of Media RelationsGreenLight Biosciences[email protected]For the press, send an e-mail: [email protected]For investors, send an e-mail: [email protected]

Notes to Editors

  1. GreenLight developed a Covid vaccine prior to this announcement. More details can be found here: https://www.greenlightbiosciences.com/greenlight-envi-and-iavi-begin-work-on-omicron-variant-adapted-covid-19-vaccine-candidate/
  2. GreenLight is designing three messenger RNA products, including a shingles vaccine with the Serum Institute of India (SII), the world’s largest vaccine producer. SII also has the potential to further extend the relationship for two other vaccine or therapeutic targets. https://greenlightbiosciences.com/greenlight-biosciences-holdings-pbc-grna-enters-into-multitarget-licensing-agreement-with-serum-institute-of-india-to-develop-and-commercialize-messenger-rna- products-for-emerging-markets-around-the-world/
  3. GreenLight’s Human Health Advisory Board includes Barney Graham, named one of Time magazine’s 2021 Heroes of the Year for his role in developing the COVID-19 vaccine: https://www.greenlightbiosciences.com /co-developer-of-covid-19-vaccine-joint-greenlight-advisory-board/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/826c004a-589b-4c5e-bc03-136ffec49bec

main logo

Image GreenLight Woburn

GreenLight researches RNA solutions at its Human Health Lab in Woburn, MA

Source: GreenLight Biosciences